{
    "nct_id": "NCT04629248",
    "official_title": "A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy",
    "inclusion_criteria": "* Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening\n* Screening urinary protein-to-creatinine ratio (UPCR) >= 5 g/g from 24-hour urine collection after best supportive care for >= 3 months prior to screening or screening UPCR >= 4 g/g after best supportive care for >= 6 months prior to screening\n* eGFR >= 40 mL/min/1.73m^2 or qualified endogenous creatinine clearance >= 40 mL/min/1.73m^2 based on 24-hour urine collection during screening\n* Other inclusion criteria may apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Participants with a secondary cause of MN\n* Pregnancy or breastfeeding\n* Evidence of >= 50% reduction in proteinuria during the previous 6 months prior to randomization\n* Severe renal impairment, including the need for dialysis or renal replacement therapy\n* Type 1 or 2 diabetes mellitus\n* Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to or during screening; or cyclophosphamide, tacrolimus, or cyclosporin less than 6 months prior to or during screening\n* Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation\n* Known active infection of any kind or recent major episode of infection\n* Major surgery requiring hospitalization within the 4 weeks prior to screening\n* Current active alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening\n* Intolerance or contraindication to study therapies\n* Other exclusion criteria may apply",
    "miscellaneous_criteria": ""
}